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Synopsis 
Magnetic resonance imaging (MRI)-derived tissue-specific measures of neuronal loss and 
demyelination were assessed at the lumbosacral level of the spinal cord (SC) in relation to neurological 
dysfunction. Acquisition of grey and white matter measures for the lumbosacral SC proved feasible, and 
were sensitive to detect tissue-specific changes in two neurological disorders commonly associated with 
lumbosacral cord involvement: Multiple system atrophy and Multiple sclerosis. This preliminary study 
demonstrates the utility of this cutting edge MRI acquisition method to detect pathological changes in 
the lumbosacral SC, and is a first step towards establishing new MRI biomarkers for these patient 
groups. 
 
Purpose 
Neurological diseases commonly affect the spinal cord (SC), resulting in significant impairment of 
mobility and other functions depending upon the level and location of lesion, and has a tremendous 
impact on health-related quality of life. Magnetic resonance imaging (MRI) has been used extensively 
to study the SC, and damage to the upper SC is associated with motor and sensory dysfunction in 
disorders such as Multiple sclerosis (MS)1. Moreover, specialised sequences such as magnetisation 
transfer imaging provide further insight into the pathophysiology of neurological diseases2,3. The lower 
SC plays a crucial role in the neurological control of lower limb and lower urinary tract (LUT) functions, 
however remains largely unexplored4. Recent studies in healthy volunteers have established new MRI 
acquisition and analysis protocols to identify the lumbosacral enlargement (LSE) and to obtain grey 
matter (GM) and white matter (WM) specific cross-sectional area (CSA) as well as magnetisation 
transfer ratio (MTR) measures2,5.  
 
The objective of this study was to apply these protocols for the first time in neurological patients with 
clinical evidence for lower SC lesion. In MS, demyelinating lesions in this region may manifest with 
voiding difficulties and urinary retention. In an uncommon neurodegenerative disorder, Multiple system 
atrophy (MSA), progressive neuronal atrophy affects several regions of the central nervous system, 
particularly the lower SC, typically manifesting with early-onset LUT dysfunction and neurophysiological 
changes. The main aim of this pilot study was to test tissue-specific CSA and MTR measures obtained 
from the LSE in individuals with suspected neurodegenerative changes in the lumbosacral spinal cord, 
in relation to clinical symptom scores. 
 
Methods 
Eleven women with MS, Expanded Disability Status Scale (EDSS)<7 and reporting different degrees of 
LUT symptoms (e.g. without, mainly voiding, and/or storage problems), as well as 15 individuals with 
“probable MSA” (7 women) with clinical and neurophysiological features suggesting sacral SC 
dysfunction were included for this study. Corresponding healthy control (HC) groups were matched for 
age and gender. Group characteristics are summarized in Table 1. A cutting edge high-resolution 3T 
MRI acquisition protocol5 was used obtaining nineteen axial contiguous slices aligned perpendicular to 
the cord starting from the superior margin of the T11 vertebral body for individual detection of the 
lumbosacral enlargement (LSE) and to obtain mean cross-sectional area (CSA) of 3 slices spanning the 
LSE (LSE-CSA) and corresponding tissue-specific CSA (i.e. LSE-CSA-WM and LSE-CSA-GM) 
measures. A recently published MTR acquisition protocol2 was used providing corresponding MTR 
measures for the same SC segments (LSE-MTR, LSE-MTR-GM and LSE-MTR-WM). The Urinary 
Symptom Profile (USP) questionnaire was used to evaluate voiding and storage LUT symptoms. 
Neurological symptoms were assessed using the Unified Multiple System Atrophy Rating Scale 
(UMSARS) and EDSS in MSA and MS, respectively. For each patient group, tissue-specific CSA and 
MTR measures were compared with those of the respective HCs using multiple analyses of variance 
(MANOVA) with post-hoc tests. Exploratory correlations were calculated for MRI-derived measures with 
LUT and neurological symptom scores. 
 
Results 
Table 2 summarizes mean MRI measures with corresponding group comparisons. Multivariate analyses 
of variance revealed a main effect for MSA across LSE-CSA-GM&WM assessments, F(2,25)=4.308, 
p=0.025, with a significant reduction in LSE-CSA-GM compared to HC, F(1,26)=8.960, p=0.006, when 
tested per tissue type. There were no significant effects (p>0.1) for MTR measures, gender or 
interactions. In MS, the MANOVA revealed a statistical trend, F(2,21)=2.917, p=0.076 across LSE-CSA-
GM&WM assessments; with smaller LSE-CSA-GM in MS compared to HC (Table 2). Mean MTR 
measures seemed to be smaller but quite variable among individuals with MS and did not reach 
statistical significance.  
In MSA, the degree of voiding symptoms was significantly (p<0.05) correlated with changes in CSA-
GM, but with opposite changes in CSA-WM (increase in voiding difficulties  decrease in CSA-GM). In 
MS, however, voiding symptoms were related to changes in MTR assessments with smaller values 
relating to bigger voiding problems. Significant correlations were found for CSA-WM with decreasing 
values being related to larger storage symptom and EDSS scores. 
 
Discussion and Conclusion 
For the first time, this recently established lumbosacral SC MRI assessment was shown to be feasible 
to use in neurological patients and was sensitive to detect tissue- and modality-specific abnormalities in 
individuals with MSA and MS, where lower SC involvement is clinically suspected. This study is an 
important initial step towards exploring new MRI biomarkers for the lumbosacral SC that may be useful 
to detect subtle symptom- and treatment-related changes in neurodegenerative conditions. A larger 
study, however, is required to confirm these findings and explore the utility of this MRI protocol across 
a larger spectrum of neurological disorders where the lower SC may be affected.  
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Table 1 Group characteristics 
 
      
 N MSA N HCMSA  Statistics  
p value 
Female:male 15 7:8 15 7:8 n.s. a 
Age [years] 
Mean (SD) 
20 59.1 (8.0) 20 55.1 (11.4) n.s. 
USP-LS [score] 
Mean (SD) 
13 4.4 (3.7) 8 0.0 (0.0) 0.001* 
USP-OAB [score] 
Mean (SD) 
13 8.7 (4.6) 8 1.8 (2.1) 0.001* 
UMSARS I [score] 
Mean (SD) 
8 22.9 (7.3)  n/a  
UMSARS II [score] 
Mean (SD) 
8 20.3 (8.7)  n/a  
UMSARS III [score] 
Mean (SD) 
8 2.5 (1.3)  n/a  
 N MS N HCMSA Statistics  
p value 
Age [years] 
Mean (SD) 
12 44.7 (10.9) 12 41.0 (14.1) n.s. 
USP-LS [score] 
Mean (SD) 
11 1.7 (2.0) 7 0.0 (0.0) 0.017* 
USP-OAB [score] 
Mean (SD) 
11 8.2 (5.5) 7 1.4 (2.3) 0.003* 
EDSS [score] 
Mean (SD) 
12 2.6 (2.4)  n/a 
 
 
Table 1. N: sample size; Urinary Symptom Profile (USP) questionnaire providing voiding – i.e. low 
stream (USP-LS, score range: 0 to 9) and storage – i.e. overactive bladder (USP-OAB, score range: 0 
to 21) symptoms; n.s.: Non-significant; N/A: Not applicable; Student’s t-tests and (a) Pearson’s chi-
square tests with χ² values were used; * indicating statistical significance for p<0.05. 
 
 
  
Table 2 
     
 
MRI measure 
 
  
MSA 
Mean (SD) 
 
HCMSA 
Mean (SD) 
 
t-test 
p value 
 Male 58.2 (3.9) 58.6 (2.6) 0.820 
LSE-CSA Female 55.6 (4.7) 57.2 (2.8) 0.447 
 Total 57.0 (4.4) 58.0 (7.2) 0.471 
 Male 20.8 (1.4) 23.8 (1.8) 0.002* 
LSE-CSA-GM Female 21.4 (2.8) 23.3 (2.9) 0.227 
 Total 21.1 (2.1) 23.6 (2.3) 0.004* 
 Male 37.4 (3.5) 34.8 (3.4) 0.152 
LSE-CSA-WM Female 34.2 (5.0) 33.9 (2.6) 0.893 
 Total 35.9 (4.4) 34.4 (3.0) 0.274 
 Male 38.7 (5.0) 39.5 (6.7) 0.803 
LSE-MTR Female 38.1 (6.5) 43.0 (5.6) 0.157 
 Total 38.4 (5.6) 41.1 (6.3) 0.224 
 Male 37.7 (4.7) 38.9 (6.2) 0.668 
LSE-MTR-GM Female 37.6 (7.2) 42.3 (5.4) 0.205 
 Total 37.7 (5.8) 40.5 (5.9) 0.203 
 Male 40.0 (5.9) 39.6 (7.6) 0.909 
LSE-MTR-WM Female 38.9 (4.4) 44.1 (6.5) 0.105 
 Total 39.5 (5.1) 41.7 (7.3) 0.339 
 
MRI measure 
 
 
 
 
MS 
Mean (SD) 
 
HCMS 
Mean (SD) 
 
t-test 
p value 
LSE-CSA  55.9 (6.5) 59.6 (6.5) 0.181 
LSE-CSA-GM  20.0 (3.3) 23.4 (3.8) 0.030* 
LSE-CSA-WM  35.9 (4.4) 36.2 (4.0) 0.884 
LSE-MTR  37.1 (7.2) 41.3 (5.8) 0.131 
LSE-MTR-GM  36.3 (7.4) 40.3 (5.8) 0.156 
LSE-MTR-WM  38.1 (7.0) 42.6 (6.1) 0.110 
Table 2 Student’s t-tests were used; * indicating statistical significance for p<0.05. LSE: lumbosacral 
enlargement, CSA: Cross-sectional area, GM: Grey matter, WM: White matter, MTR: magnetisation 
transfer ratio,  
 
